<html><body><pre>
[Congressional Bills 113th Congress]
[From the U.S. Government Printing Office]
[S. 2917 Enrolled Bill (ENR)]

        S.2917

                     One Hundred Thirteenth Congress

                                 of the

                        United States of America


                          AT THE SECOND SESSION

           Begun and held at the City of Washington on Friday,
           the third day of January, two thousand and fourteen


                                 An Act


 
  To expand the program of priority review to encourage treatments for 
                           tropical diseases.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
    This Act may be cited as the ``Adding Ebola to the FDA Priority 
Review Voucher Program Act''.
SEC. 2. PRIORITY REVIEW TO ENCOURAGE TREATMENTS FOR TROPICAL DISEASES.
    Section 524 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
360n) is amended--
        (1) in subsection (a)(3)--
            (A) by redesignating subparagraph (Q) as subparagraph (R);
            (B) by inserting after subparagraph (P) the following:
            ``(Q) Filoviruses.''; and
            (C) in subparagraph (R), as so redesignated, by striking 
        ``regulation by'' and inserting ``order of''; and
        (2) in subsection (b)--
            (A) in paragraph (2), by adding ``There is no limit on the 
        number of times a priority review voucher may be transferred 
        before such voucher is used.'' after the period at the end; and
            (B) in paragraph (4), by striking ``365 days'' and 
        inserting ``90 days''.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
</pre></body></html>
